Pharmacology of P2X channels

被引:251
作者
Gever, Joel R.
Cockayne, Debra A.
Dillon, Michael P.
Burnstock, Geoffrey
Ford, Anthony P. D. W.
机构
[1] Roche Palo Alto, Dept Biochem Pharmacol, Palo Alto, CA 94304 USA
[2] Roche Palo Alto, Dept Neurosci, Palo Alto, CA 94304 USA
[3] Roche Palo Alto, Dept Med Chem, Palo Alto, CA 94304 USA
[4] UCL Royal Free & Univ Coll Med Sch, Autonom & Neurosci Ctr, London NW3 2PF, England
来源
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY | 2006年 / 452卷 / 05期
关键词
P2X; purinergic; ATP; ion channel; antagonist;
D O I
10.1007/s00424-006-0070-9
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Significant progress in understanding the pharmacological characteristics and physiological importance of homomeric and heteromeric P2X channels has been achieved in recent years. P2X channels, gated by ATP and most likely trimerically assembled from seven known P2X subunits, are present in a broad distribution of tissues and are thought to play an important role in a variety of physiological functions, including peripheral and central neuronal transmission, smooth muscle contraction, and inflammation. The known homomeric and heteromeric P2X channels can be distinguished from each other on the basis of pharmacological differences when expressed recombinantly in cell lines, but whether this pharmacological classification holds true in native cells and in vivo is less well-established. Nevertheless, several potent and selective P2X antagonists have been discovered in recent years and shown to be efficacious in various animal models including those for visceral organ function, chronic inflammatory and neuropathic pain, and inflammation. The recent advancement of drug candidates targeting P2X channels into human trials, confirms the medicinal exploitability of this novel target family and provides hope that safe and effective medicines for the treatment of disorders involving P2X channels may be identified in the near future.
引用
收藏
页码:513 / 537
页数:25
相关论文
共 50 条
  • [41] Purine lonotropic (P2X) receptors
    Koeles, L.
    Fuerst, S.
    Illes, P.
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (23) : 2368 - 2384
  • [42] P2X Receptors as Drug Targets
    North, R. Alan
    Jarvis, Michael F.
    MOLECULAR PHARMACOLOGY, 2013, 83 (04) : 759 - 769
  • [43] P2X receptors and acupuncture analgesia
    Tang, Yong
    Yin, Hai-yan
    Lu, Juan
    Rubini, Patrizia
    Illes, Peter
    BRAIN RESEARCH BULLETIN, 2019, 151 : 144 - 152
  • [44] Molecular properties of P2X receptors
    Jonathan A. Roberts
    Catherine Vial
    Helen R. Digby
    Kelvin C. Agboh
    Hairuo Wen
    Amelia Atterbury-Thomas
    Richard J. Evans
    Pflügers Archiv, 2006, 452 : 486 - 500
  • [45] An evolutionary history of P2X receptors
    Samuel J. Fountain
    Geoffrey Burnstock
    Purinergic Signalling, 2009, 5 : 269 - 272
  • [46] Molecular properties of P2X receptors
    Roberts, Jonathan A.
    Vial, Catherine
    Digby, Helen R.
    Agboh, Kelvin C.
    Wen, Hairuo
    Atterbury-Thomas, Amelia
    Evans, Richard J.
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2006, 452 (05): : 486 - 500
  • [47] P2X purinergic receptor ligands: recently patented compounds
    Gunosewoyo, Hendra
    Kassiou, Michael
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (05) : 625 - 646
  • [48] Exploring the ATP-binding site of P2X receptors
    Chataigneau, Thierry
    Lemoine, Damien
    Grutter, Thomas
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2013, 7
  • [49] Nociceptive signaling of P2X receptors in chronic pain states
    Inoue, Kazuhide
    PURINERGIC SIGNALLING, 2021, 17 (01) : 41 - 47
  • [50] Contribution of P2X purinergic receptor in cerebral ischemia injury
    Zhang, Wen -Jun
    Hu, Dong-Xia
    Lin, Si-Jian
    Fang, Xiao-Qun
    Ye, Zhen-Feng
    BRAIN RESEARCH BULLETIN, 2022, 190 : 42 - 49